Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04665115
Recruitment Status : Withdrawn (Permanently closed 11/19/201. The widespread availability of COVID vaccination, the projected decline in infection rates, and the increasing use of non-ibrutinib containing BTKi therapy, we have not been able to get support for this study)
First Posted : December 11, 2020
Last Update Posted : August 3, 2022
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Academic and Community Cancer Research United

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Actual Primary Completion Date : November 19, 2021
Actual Study Completion Date : July 22, 2022